Publications

Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial

By:
Contributors: Jackson Wu, MSc, MD, FRCP
Lancet Oncol. 2014 Feb;15(2):164-71. doi: 10.1016/S1470-2045(13)70556-4. Epub 2013 Dec 23.

Abstract

BACKGROUND:

Although repeat radiation treatment has been shown to palliate pain in patients with bone metastases from multiple primary origin sites, data for the best possible dose fractionation schedules are lacking. We aimed to assess two dose fractionation schedules in patients with painful bone metastases needing repeat radiation therapy.

METHODS:

We did a multicentre, non-blinded, randomised, controlled trial in nine countries worldwide. We enrolled patients 18 years or older who had radiologically confirmed, painful (ie, pain measured as ≥2 points using the Brief Pain Inventory) bone metastases, had received previous radiation therapy, and were taking a stable dose and schedule of pain-relieving drugs (if prescribed). Patients were randomly assigned (1:1) to receive either 8 Gy in a single fraction or 20 Gy in multiple fractions by a central computer-generated allocation sequence using dynamic minimisation to conceal assignment, stratified by previous radiation fraction schedule, response to initial radiation, and treatment centre. Patients, caregivers, and investigators were not masked to treatment allocation. The primary endpoint was overall pain response at 2 months, which was defined as the sum of complete and partial pain responses to treatment, assessed using both Brief Pain Inventory scores and changes in analgesic consumption. Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00080912.

FINDINGS:

Between Jan 7, 2004, and May 24, 2012, we randomly assigned 425 patients to each treatment group. 19 (4%) patients in the 8 Gy group and 12 (3%) in the 20 Gy group were found to be ineligible after randomisation, and 140 (33%) and 132 (31%) patients, respectively, were not assessable at 2 months and were counted as missing data in the intention-to-treat analysis. In the intention-to-treat population, 118 (28%) patients allocated to 8 Gy treatment and 135 (32%) allocated to 20 Gy treatment had an overall pain response to treatment (p=0·21; response difference of 4·00% [upper limit of the 95% CI 9·2, less than the prespecified non-inferiority margin of 10%]). In the per-protocol population, 116 (45%) of 258 patients and 134 (51%) of 263 patients, respectively, had an overall pain response to treatment (p=0·17; response difference 6·00% [upper limit of the 95% CI 13·2, greater than the prespecified non-inferiority margin of 10%]). The most frequently reported acute radiation-related toxicities at 14 days were lack of appetite (201 [56%] of 358 assessable patients who received 8 Gy vs 229 [66%] of 349 assessable patients who received 20 Gy; p=0·011) and diarrhoea (81 [23%] of 357 vs 108 [31%] of 349; p=0·018). Pathological fractures occurred in 30 (7%) of 425 patients assigned to 8 Gy and 20 (5%) of 425 assigned to 20 Gy (odds ratio [OR] 1·54, 95% CI 0·85-2·75; p=0·15), and spinal cord or cauda equina compressions were reported in seven (2%) of 425 versus two (<1%) of 425, respectively (OR 3·54, 95% CI 0·73-17·15; p=0·094).

INTERPRETATION:

In patients with painful bone metastases requiring repeat radiation therapy, treatment with 8 Gy in a single fraction seems to be non-inferior and less toxic than 20 Gy in multiple fractions; however, as findings were not robust in a per-protocol analysis, trade-offs between efficacy and toxicity might exist.

 

PubMed

Download PDF

 

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Prostate Cancer Canada’s Step Up Challenge 2019!

Prostate Cancer Canada’s Step Up Challenge 2019 pits endurance and drive against multistory office tower stairwells and gravity to raise funds for local prostate cancer research projects and initiatives in four Canadian cities. Heroic participants challenged the stairs in Toronto and Calgary on March 3rd, still to come is Vancouver on March 10th and Edmonton on March 17th (St. Patricks day!).

Congratulations to Calgary’s Step Up Challenge event participants who raised 111% of their $95 000 goal! These proceeds will support Dr. Tarek Bismar’s team at the University of Calgary. They are using blood samples from men with slow-growing prostate cancer that has not spread outside the prostate to determine if their disease is likely to advance. Learn more about this project from APCaRI and the Prostate cancer Collaborative Research Alliance.

Edmonton’s Step Up Challenge event is actively raising funds to support Dr. Kerry Courneya’s team at the University of Alberta, with 30% of the $65 000 goal reached currently. Dr. Courneya is a Professor and Canada Research Chair in Physical Activity and Cancer and Director of The Behavioral Medicine Laboratory and Fitness Center. This project is being led by doctoral student Dong-woo (Derek) Kang and will study whether exercise can reduce tumour growth and anxiety for men on active surveillance. Learn more about this project that could contribute to delaying, or even eliminating, the need for treatment from the Behavioral Medicine Laboratory and Fitness Center.

Dr. Kerry Courneya

ERASE-Scientific-Abstract

Please support the Edmonton Step Up Challenge 2019 as either a participant, or donor, or both!
The Lewis lab has entered Team Nanosteps into the challenge, check out our fundraising page and support the team by clicking on this link and making a secure online donation using your credit card.

Kerry Courneya’s Behavioral Medicine Lab team is also hitting the stairs, please click here to go to their Step Up Challenge team page to sponsor them with a donation as well!

Thanks in advance for any support you are able to provide. Get your runners and see you on March 17th!

- Perrin Beatty